FDA, AAMI Explore How To Consider Benefits, Risks In Postmarket
This article was originally published in The Gray Sheet
Executive Summary
FDA has already put a lot of work into mapping out pathways for weighing benefit versus risk in premarket review decisions. Now the agency, with the help of the Association for the Advancement of Medical Instrumentation and industry, is trying to provide the same support for compliance and enforcement decisions.